ストックスクリーナーアプリを入手
374.53
2.56%
-9.79
前日終値:
$384.32
開ける：
$380.7
24時間の取引高:
1.25M
Relative Volume:
0.43
時価総額：
$201.87B
収益：
$36.71B
当期純損益:
$7.71B
株価収益率:
26.32
EPS:
14.2284
ネットキャッシュフロー:
$9.96B
1週間 パフォーマンス:
+8.65%
1か月 パフォーマンス:
+14.84%
6か月 パフォーマンス:
+29.93%
1年 パフォーマンス:
+27.58%
1日の値動き範囲:
$372.34
$384.62
1週間の範囲:
$338.59
$385.12
52週間の値動き範囲:
$261.43
$385.12
Amgen Inc Stock (AMGN) Company Profile
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
374.53 | 207.15B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,051.72 | 947.09B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
237.36 | 578.21B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
221.21 | 394.89B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
156.38 | 298.47B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
188.62 | 299.25B | 58.07B | 9.40B | 9.87B | 3.0115 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
When Advocacy Meets Science in the Care of People Living with gMG - Amgen
Amgen, Merck share losses contribute to Dow's 200-point drop - MSN
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
ProShare Advisors LLC Sells 158,994 Shares of Amgen Inc. $AMGN - MarketBeat
Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Acquires 2,967 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock price hits 52-week high after Friday rally — what to watch into Monday - TechStock²
The Truth About Amgen Inc.: Is This Quiet Biotech Giant Your Next Power Move? - AD HOC NEWS
Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440 - TIKR.com
Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN - MarketBeat
Renaissance Group LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
SBI Securities Co. Ltd. Has $977,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Sees Target Price Increase by Argus Research | AMGN Stock News - GuruFocus
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
Argus Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma - TipRanks
Amgen (AMGN) Target Price Raised by Guggenheim Analyst | AMGN St - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $347.00 - MarketBeat
Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating - marketscreener.com
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating - marketscreener.com
Aurdan Capital Management LLC Sells 5,316 Shares of Amgen Inc. $AMGN - MarketBeat
3,190 Shares in Amgen Inc. $AMGN Acquired by ABN AMRO Bank N.V. - MarketBeat
Biotechnology Market Set to Witness Significant Growth by 2026-2033 | Amgen Inc., GlaxoSmithKline - EIN News
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Cancer Supportive Care Drugs Market Is Going to Boom | Amgen Inc., - openPR.com
Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions - Yahoo Finance
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) - marketscreener.com
CVS Health to drop Amgen and Lilly’s bone disease treatments from some drug lists - WKZO
Key facts: Amgen's stock soars 8% on strong earnings; CVS to drop Prolia - tradingview.com
RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum - Finviz
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch - TipRanks
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu - Citeline News & Insights
Why is Amgen stock falling premarket? - MSN
Why Is Amgen Stock Falling Premarket? - Stocktwits
BI Asset Management Fondsmaeglerselskab A S Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Jones Financial Companies Lllp Has $10.89 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026 - Meyka
Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains - Yahoo Finance
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open - TechStock²
Amgen Earnings Call: Broad Growth Amid Manageable Risks - TipRanks
Amgen (AMGN) Surges on Q4 Earnings Beat, Leading Dow Gains - GuruFocus
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
1.10%
3.66%
大文字化:
|
ボリューム (24 時間):